Why We Don’t Use Neuroleptics for Routine Insomnia
Antipsychotics can absolutely make people sleepy. That is not the same thing as meaning they are a good idea for routine insomnia. Sedation is not the same as a good risk-benefit balance, and for ordinary sleep problems, the price of these medications is often much higher than the benefit they provide.
You might have heard of medications like Quetiapine (Seroquel) being used "off-label" to help with sleep. While they definitely "knock you out," they are heavy-duty medications designed for serious psychiatric conditions (like schizophrenia or bipolar disorder).
Using them *just* for sleep is often a poor trade-off because of the side effects:
- Metabolic Risk: Significant weight gain and increased risk of diabetes.
- Morning Fog: A heavy "hangover" feeling that lasts long into the next day.
- Movement Issues: Long-term use can lead to permanent twitching or restlessness.
For routine insomnia, we have much safer tools—like CBT-I or targeted sleep medications—that help you rest without the baggage of an antipsychotic.
The use of second-generation antipsychotics (SGAs) (e.g., Quetiapine, Olanzapine) as primary hypnotics for non-psychotic insomnia is strongly discouraged by the AASM and the American Psychiatric Association (APA).
The Risk-Benefit Ratio
- Metabolic Sequelae: SGAs are associated with rapid weight gain, dyslipidemia, and insulin resistance. Even low doses of quetiapine (25–50mg) can negatively impact metabolic health over time.
- Movement Disorders: The risk of Tardive Dyskinesia (TD) and Extrapyramidal Symptoms (EPS) exists even with low-dose chronic exposure.
- Cognitive and Motor Impairment: Next-day sedation is prominent, increasing the risk for falls in elderly patients and impaired driving in younger ones.